Bisphosphonate-associated osteomyelitis of the jaw: Guidelines for practicing clinicians

Endocrine Practice

Volumn 14, Issue 9, 2008, Pages 1150-1168

  Wimalawansa, Sunil J ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; AMOXICILLIN; BISPHOSPHONIC ACID DERIVATIVE; CHLORHEXIDINE GLUCONATE; CLODRONIC ACID; CORTICOSTEROID; ETIDRONIC ACID; IBANDRONIC ACID; INCADRONIC ACID; MOUTHWASH; PAMIDRONIC ACID; PENICILLIN V; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID; ANGIOGENESIS INHIBITOR; BONE DENSITY CONSERVATION AGENT;

BISPHOSPHONATE ASSOCIATED OSTEOMYELITIS OF THE JAW; CANCER CHEMOTHERAPY; DEBRIDEMENT; DENTAL CARE; DENTAL SURGERY; DIABETES MELLITUS; DRUG INDUCED DISEASE; HISTOLOGY; HUMAN; HYPERBARIC OXYGEN; IMMUNE STATUS; JAW OSTEONECROSIS; MANDIBLE; MAXILLA; MOUTH HYGIENE; MOUTH INFECTION; OSTEOMYELITIS; OSTEOPOROSIS; PAGET BONE DISEASE; PERIODONTAL DISEASE; PRACTICE GUIDELINE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; TOOTH EXTRACTION; ANGIOGENESIS; BIOLOGICAL MODEL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; JAW DISEASE; WOUND HEALING;

ANGIOGENESIS INHIBITORS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; JAW DISEASES; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOMYELITIS; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; WOUND HEALING;

EID: 64049103096     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.9.1150     Document Type: Review

References (160)

1. Fleisch H. Bisphosphonates in Bone Disease: From the Laboratory to the Patient. 4th ed. San Diego, CA: Academic Press, 2000.
2. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733-759.
3. Russell G, Mueller G, Shipman C, Croucher P. Clinical disorders of bone resorption [with discussion]. Novartis Found Symp. 2001;232:251-271.
4. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper [published correction appears in J Am Dent Assoc. 2006;137:26]. J Am Dent Assoc. 2005;136:1658-1668.
5. Wickersham RM, Novak KK, eds. Drug Facts and Comparisons. St. Louis, MO: Wolters Kluwer Health, Inc., 2006.
6. Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007;1117:209-257.
7. Licata AA. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother. 2005;39:668-677.
8. Lipton A. New therapeutic agents for the treatment of bone diseases. Expert Opin Biol Ther. 2005;5:817-832.
9. Watts NB, Lewiecki EM, Miller PD, Baim S. National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom. 2008;12:25-31.
10. Little DG, McDonald M, Sharpe IT, Peat R, Williams P, McEvoy T. Zoledronic acid improves femoral head sphericity in a rat model of Perthes disease. J Orthop Res. 2005;23:862-868.
11. Adachi H, Igarashi K,Mitani H, Shinoda H. Effects of topical administration of a bisphosphonate (risedronate) on orthodontic tooth movements in rats. J Dent Res. 1994;73:1478-1486.
12. Liu L, Igarashi K, Haruyama N, Saeki S, Shinoda H, Mitani H. Effects of local administration of clodronate on orthodontic tooth movement and root resorption in rats. Eur J Orthod. 2004;26:469-473.
13. Reddy MS, Weatherford TW III, Smith CA, West BD, Jeffcoat MK, Jacks TM. Alendronate treatment of naturally-occurring periodontitis in beagle dogs. J Periodontol. 1995;66:211-217.
14. Schindeler A, Little DG. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. Biochem Biophys Res Commun. 2005;338:710-716.
15. Bobyn JD, Hacking SA, Krygier JJ, Harvey EJ, Little DG, Tanzer M. Zoledronic acid causes enhancement of bone growth into porous implants. J Bone Joint Surg Br. 2005;87:416-420.
16. Berenson JR, Hillner BE, Kyle RA, et al (American Society of Clinical Oncology Bisphosphonates Expert Panel). American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719-3736.
17. Hillner BE, Ingle JN, Chlebowski RT, et al (American Society of Clinical Oncology). American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer [published correction appears in J Clin Oncol. 2004;22:1351]. J Clin Oncol. 2003;21:4042-4057.
18. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63:1567-1575.
19. Hoff AO, Toth BB, Altundag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol. 2006;24:8528.
20. Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med. 2004;117:440-441.
21. Tosi P, Zamagni E, Cangini D, et al. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood. 2006;108:3951-3952.
22. Tosi P, Zamagni E, Cangini D, et al. Bisphosphonates and osteonecrosis of the jaws: incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zoledronic acid [abstract]. Blood. 2005;106:3461.
23. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment [published correction appears in Lancet Oncol. 2006;7:533]. Lancet Oncol. 2006;7: 508-514.
24. Mashiba T, Mori S, Burr DB, et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab. 2005; 23(suppl):36-42.
25. Wimalawansa SJ. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy. Clin Endocrinol (Oxf). 1994;41:591-595.
26. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws [published correction appears in Ann Intern Med. 2006;145:235]. Ann Intern Med. 2006;144:753-761.
27. Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaw and bisphosphonates [with discussion]. N Engl J Med. 2005;353:99-102.
28. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001;28:524-531.
29. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-1117.
30. Olson KB, Hellie CM, Pienta KJ. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. Urology. 2005;66:658.
31. Saad F. Bone-directed treatments for prostate cancer. Hematol Oncol Clin North Am. 2006;20:947-963.
32. Pastor-Zuazaga D, Garatea-Crelgo J, Martino-Gorbea R, Etayo-Pérez A, Sebastián-López C. Osteonecrosis of the jaws and bisphosphonates: report of three cases [article in Spanish]. Med Oral Patol Oral Cir Bucal. 2006;11:E76-E79.
33. Weitzman R, Sauter N, Eriksen EF, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients - May 2006. Crit Rev Oncol Hematol. 2007;62:148-152.
34. Thakkar SG, Isada C, Smith J, et al. Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias. Med Oncol. 2006;23:51-56.
35. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg. 2003;61:1104-1107.
36. Wimalawansa SJ. Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opin Drug Saf. 2008;7:491-512.
37. Chang JS. ODS Postmarketing Safety Review. 2004. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4095B2-03-04-FDA-TAB3.pdf. Accessed for verification September 7, 2008.
38. Farrugia MC, Summerlin DJ, Krowiak E, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope. 2006;116:115-120.
39. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc. 2005;36:1675-1681.
40. Food and Drug Administration Center for Drug Evaluation and Research Oncologic Drugs Advisory Committee meeting March 4, 2005: questions to the committee. http://www.fda.gov/ohrms/dockets/ac/05/questions/2005-4095Q2-02- Zometa-Aredia-Questions. pdf. Accessed for verification September 7, 2008.
41. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc. 2006;137:1144-1150.
42. Bilezikian JP. Osteonecrosis of the jaw - do bisphosphonates pose a risk? N Engl J Med. 2006;355:2278-2281.
43. U.S. Food and Drug Administration. MedWatch 2004 Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements: Zometa (zoledronic acid) injection. http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#zometa. Accessed for verification September 7, 2008.
44. Khosla S, Burr D, Cauley J, et al (American Society for Bone andMineral Research). Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-1491.
45. Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws. LDA J. 2005;64:21-24.
46. Melo MD, Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc. 2005;71:111-113.
47. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. September 25, 2006. http://www.aaoms.org/docs/position-papers/osteonecrosis.pdf. Accessed for verification December 18, 2008.
48. Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi P. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. J Oral Pathol Med. 2005;34:613-617.
49. Harrison M, James N, Broadley K, et al. Somatostatin analogue treatment for malignant hypercalcaemia [published correction appears in BMJ. 1990;301:97]. BMJ. 1990;300:1313-1314.
50. Wimalawansa SJ. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer. 1994;73:2223-2230.
51. Wimalawansa S. Hypercalcaemia of malignancy: etiology, pathophysiology, and management. Rev Endocr Relat Cancer. 1993;45:5-24.
52. Wimalawansa S. Hypercalcaemia of Malignancy: Etiology, Pathogenesis and Clinical Management. Austin, TX: R G Landes Co Inc, 1995.
53. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006;12(20, pt 2):6222s-6230s.
54. Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonateinduced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002;109:1041-1048.
55. Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res. 1998;13:793-802.
56. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274-282.
57. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21: 115-137.
58. Sarathy AP, Bourgeois SL Jr, Goodell GG. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports [published correction appears in J Endod. 2005;31:835-836]. J Endod. 2005;31:759-763.
59. Wooltorton E. Patients receiving intravenous bisphosphonates should avoid invasive dental procedures. CMAJ. 2005;172:1684.
60. Treister N, Woo SB. Images in clinical medicine: bisphosphonate-associated osteonecrosis of the jaw. N Engl J Med. 2006;355:2348.
61. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone. 2007;41:318-320.
62. Hansen T, KunkelM,Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006;35:155-160.
63. Märten A, Lilienfeld-Toal M, Büchler MW, Schmidt J. Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells. J Immunother. 2007;30:370-377.
64. Wolf AM, Rumpold H, Tilg H, Gastl G, Gunsilius E, Wolf D. The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica. 2006;91:1165-1171.
65. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human gammadelta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007;67:7450-7457.
66. Sato K, Kimura S, Segawa H, et al. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer. 2005;116:94-99.
67. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 2007;67:11438-11446.
68. Fiore F, Castella B, Nuschak B, et al. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood. 2007;110:921-927.
69. Khosla S, Burr D, Cauley J, et al (American Society for Bone andMineral Research). Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-1491.
70. Cafro A, Barbarano LA, Andriani A, et al. Osteonecrosis of the jaw associated with chronic bisphosphonate therapy: an Italian experience [American Society of Hematology Annual Meeting Abstracts]. Blood. 2005;106:5152.
71. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg. 2005;63:682-689.
72. The Maxillofacial Center for Diagnostics & Research. The History of Maxillofacial Osteonecrosis (NICO). http://maxillofacialcenter.com/ NICOhistory.html#Histo ry. Accessed for verification September 7, 2008.
73. Merck & Co., Inc. Fosamax (alendronate sodium) tablets and oral solution. Whitehouse Station, NJ; February 2006. http://www.fosamax.com/ fosamax/shared/documents/english/pi.pdf. Accessed for verification September 7, 2008.
74. Black DM, Delmas PD, Eastell R, et al (HORIZON Pivotal Fracture Trial). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.
75. Lyles KW, Colón-Emeric CS, Magaziner JS, et al (HORIZON Recurrent Fracture Trial). Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-1809.
76. Pozzi S, Marcheselli R, Sacchi S, et al (Gruppo Italiano Studio Linfomi). Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma. 2007;48:56-64.
77. Vannucchi AM, Ficarra G, Antonioli E, Bosi A. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol. 2005; 128:738.
78. Mehrotra B, Ruggiero SL. Bisphosphonate related osteonecrosis (BRON) of the jaw: single institutional update [American Society of Hematology Annual Meeting Abstracts]. Blood. 2005;106:291.
79. Vaidya S, Saika S, Sirohi B, Pai S, Advani S. Avascular necrosis of bone - a complication of aggressive therapy for acute lymphoblastic leukemia. Acta Oncol. 1998;37:175-177.
80. Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg. 2006;64:917-923.
81. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580-8587.
82. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates [with discussion] [published correction appears in N Engl J Med. 2005;353:2728]. N Engl J Med. 2005;353:99-102.
83. Markiewicz MR, Margarone JE III, Campbell JH, Aguirre A. Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc. 2005;136:1669-1674.
84. Lipton A. Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs. 2003;8:469-488.
85. Lenz JH, Steiner-Krammer B, SchmidtW, Fietkau R, Mueller PC, Gundlach KK. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? J Craniomaxillofac Surg. 2005;33:395-403.
86. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65: 415-423.
87. Felsenberg D, Hoffmeister B, Amling M. Bisphosphonattherapie assoziierte. Kiefernekrosen Deutsches Arzteblatt. 2006;46:A3078-A3080.
88. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003;9:2893-2897.
89. Pogrel MA. Bisphosphonates and bone necrosis. J Oral Maxillofac Surg. 2004;62:391-392.
90. Schwartz HC. Osteonecrosis and bisphosphonates: correlation versus causation. J Oral Maxillofac Surg. 2004; 62:763-764.
91. Davenport A, Goel S, Mackenzie JC. Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure. Scand J Urol Nephrol. 1993;27:447-451.
92. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735-1744.
93. Soileau KM. Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy. J Periodontol. 2006;77:738-743.
94. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21:4253-4254.
95. LacyMQ, Dispenzieri A, GertzMA, et al. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81:1047-1053.
96. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid [with discussion]. N Engl J Med. 2003; 349:1676-1679.
97. Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis. 2003;41:E18.
98. Novartis Pharmaceuticals Corporation. Aredia product information. East Hanover, NJ; November 2007. http://www.pharma.us.novartis.com/product/pi/ pdf/aredia.pdf. Accessed for verification September 7, 2008.
99. Machado CE, Flombaum CD. Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol. 1996;45:175-179.
100. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12: 1164-1172.
101. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64:281-289.
102. Munier A, Gras V, Andrejak M, et al. Zoledronic acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother. 2005;39:1194-1197.
103. Pozzi S, Marcheselli R, Sacchi S. Analysis of frequency and risk factors for developing bisphosphonate associated osteonecrosis of the jaw. Blood. 2005;106:5057a.
104. Liberman UA. Long-term safety of bisphosphonate therapy for osteoporosis: a review of the evidence. Drugs Aging. 2006;23:289-298.
105. McMahon RE, Bouquot JE, Glueck CJ, Griep J. Beyond bisphosphonates: thrombophilia, hypofibrinolysis, and jaw osteonecrosis. J Oral Maxillofac Surg. 2006;64:1704-1705.
106. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007;356:1895-1896.
107. Bagán J, Blade J, Cozar JM, et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal. 2007;12:E336-E340.
108. Pickett FA (American Academy of Oral Medicine). Bisphosphonate-associated osteonecrosis of the jaw: a literature review and clinical practice guidelines. J Dent Hyg. 2006;80:10.
109. Agarwala S, Sule A, Pai BU, Joshi VR. Alendronate in the treatment of avascular necrosis of the hip. Rheumatology (Oxford). 2002;41:346-347.
110. Mellström DD, Sörensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;75:462-468.
111. Hortobagyi GN, Theriault RL, Porter L, et al (Protocol 19 Aredia Breast Cancer Study Group). Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 1996;335:1785-1791.
112. Bagan JV, Jimenez Y, Murillo J, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions; study of 20 cases. Oral Oncol. 2006;42:327-329.
113. Ficarra G, Beninati F, Rubino I, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol. 2005;32:1123-1128.
114. Katz H. Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: a report of three cases. J Endod. 2005;31:831-834.
115. Grana J, Mahia IV, Meizoso MO, Vazquez T.Multiple osteonecrosis of the jaw, oral bisphosphonate therapy and refractory rheumatoid arthritis (pathological fracture associated with ONJ and BP use for osteoporosis). Clin Exp Rheumatol. 2008;26:384-385.
116. StarckWJ, Epker BN. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants. 1995;10:74-78.
117. Bianchi SD, Scoletta M, Cassione FB, Migliaretti G, Mozzati M. Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:249-258.
118. Watts NB, Marciani RD. Osteonecrosis of the jaw. South Med J. 2008;101:160-165.
119. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369-376.
120. Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonate- induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg. 2006;35:588-593.
121. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91:968-971.
122. Durie BG, KatzM, Crowley J. Osteonecrosis of the jaw and bisphosphonates [with discussion]. N Engl J Med. 2005;353:99-102.
123. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005;34:120-123.
124. Van den Wyngaert T, Huizing MT, Vermorken JB. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann Oncol. 2006;17:1197-1204.
125. Zarychanski R, Elphee E, Walton P, Johnston J. Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol. 2006;81:73-75.
126. Hess LM, Jeter JM, Benham-HutchinsM, Alberts DS. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med. 2008;121:475-483; e3.
127. Khosla S, Burr D, Cauley J, et al (American Society for Bone and Mineral Research Task Force on Osteonecrosis of the Jaw). Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment [published correction appears in J Oral Maxillofac Surg. 2008;66:1778]. J Oral Maxillofac Surg. 2008;66:1320-1321.
128. Tauchmanovà L, De Rosa G, Serio B, et al. Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review. Cancer. 2003;97:2453-2461.
129. For the dental patient: oral care for cancer patients. J Am Dent Assoc. 2002;133:1014.
130. Wimalawansa SJ. Long-term bisphosphonate therapy and increased fracture risks. J Bone Miner Res. 2007; 22(suppl 1):S456.
131. Sanna G, Zampino MG, Pelosi G, Nolè F, Goldhirsch A. Jaw avascular bone necrosis associated with long-term use of biphosphonates. Ann Oncol. 2005;16:1207-1208.
132. Mignogna MD, Fedele S, Lo Russo L, Ciccarelli R, Lo Muzio L. Case 2: osteonecrosis of the jaws associated with bisphosphonate therapy [published correction appears in J Clin Oncol. 2006;24:2687]. J Clin Oncol. 2006;24:1475-1477.
133. Wimalawansa SJ. Intermittent, intravenous pamidronate therapy: highly effective treatment for postmenopausal osteoporosis; program and abstracts from the 23rd annual meeting of the American Society for Bone and Mineral Research; October 12-16, 2001; Phoenix, Arizona [abstract SU400]. J Bone Miner Res. 2001;16(suppl 1): S405.
134. Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid [published online ahead of print August 9, 2008]. Ann Oncol.
135. Etminan M, Aminzadeh K. Bisphosphonates and ONJ [with author reply]. J Am Dent Assoc. 2008;139:535-536.
136. Glick M. Closing in on the puzzle of ONJ. J Am Dent Assoc. 2008;139:4-5.
137. La Verde N, Bareggi C, Garassino M, et al. Osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates: how the knowledge of a phenomenon can change its evolution [published online ahead of print July 29, 2008]. Support Care Cancer.
138. Shane E, Goldring S, Christakos S, et al. Osteonecrosis of the jaw: more research needed. J Bone Miner Res. 2006;21:1503-1505.
139. Leite AF, Figueiredo PT, Melo NS, et al. Bisphosphonate-associated osteonecrosis of the jaws: report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:14-21.
140. Berenson JR, Lichtenstein A, Porter L, et al (Myeloma Aredia Study Group). Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334: 488-493.
141. Migliorati CA. Bisphosphonate-associated oral osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99:135.
142. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005; 104:83-93.
143. Marx RE. Oral & Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws: History, Etiology, Prevention, and Treatment. Hanover Park, IL: Quintessence Publishing, 2006.
144. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397-2410.
145. Boniva (ibandronate sodium injection) [package insert]. Nutley, NJ: Roche Pharmaceuticals; August 2006. http://www.fda.gov/MEDWATCH/SAFETY/2007/Feb-PI/ Boniva-Inj-PPI.pdf. Accessed for verification September 7, 2008.
146. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294-1301.
147. Nitche J, Masella R, Redziniak D, Wimalawansa SJ. Subtrochanteric femoral stress fractures in patients on bisphosphonate therapy. Osteoporosis Int. In press.
148. Jeffcoat M, Watts NB. Osteonecrosis of the jaw: balancing the benefits and risks of oral bisphosphonate treatment for osteoporosis [with quiz]. Gen Dent. 2008;56: 96-104, 111-112.
149. Kademani D, Koka S, Lacy MQ, Rajkumar SV. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc. 2006;81:1100-1103.
150. Malmgren B, Aström E, Söderhäll S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med. 2008;37:196-200.
151. Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc. 2008;139:23-30.
152. Grbic JT, Landesberg R, Lin SQ, et al (Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial Research Group). Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial. J Am Dent Assoc. 2008;139:32-40.
153. Bertoldo F. Bisphosphonates and osteonecrosis of the mandible/maxilla in osteoporosis: no reason to panic. Aging Clin Exp Res. 2008;20:87-90.
154. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg. 2008;66:625-631.
155. Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg. 2008;66: 767-775.
156. Sarasquete ME, García-Sanz R, Marín L, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood. 2008;112: 2709-2712.
157. Landesberg R, CozinM, Cremers S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008;66:839-847.
158. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008;44: 857-869.
159. Lehrer S, Montazem A, Ramanathan L, et al. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:389-391.
160. Bagan JV, Jiménez Y, Gómez D, Sirera R, Poveda R, Scully C. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates [published online ahead of print April 5, 2008]. Oral Oncol.